Emergent BioSolutions Gains FDA Nod and WHO Evaluation
Company Announcements

Emergent BioSolutions Gains FDA Nod and WHO Evaluation

Emergent Biosolutions (EBS) just unveiled an update.

Emergent BioSolutions Inc. recently announced that the U.S. FDA has approved the expansion of the indication for its ACAM2000® vaccine, now including immunization against mpox disease for high-risk individuals. This comes on the heels of Emergent’s move to have the vaccine evaluated by the WHO for emergency use during the mpox outbreak.

Learn more about EBS stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyEmergent BioSolutions files to sell 3.61M shares of common stock for holders
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyEmergent BioSolutions rises 31.2%
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App